News in brief: Nexalis advances IRX-616a and IRX-211 programs; Vitura heralds Doctors on Demand growth; Elixinol improves cash flow by Adam Sheldon April 20, 2026April 22, 2026 Nexalis Therapeutics – formerly InhaleRx – has completed dosing in the first cohort of its Phase […]
